Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00798096
Other study ID # D4300C00024
Secondary ID C-935788-017
Status Completed
Phase Phase 2
First received November 21, 2008
Last updated July 25, 2014
Start date March 2009
Est. completion date April 2010

Study information

Verified date July 2014
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationCanada: Health Canada
Study type Interventional

Clinical Trial Summary

Patients meeting specific inclusion and exclusion criteria will be enrolled in two stages, 19 patients in Stage 1 and 36 patients in Stage 2. Stage 2 will enroll if 4 or more patients exhibit a response at Week 8 or later in the study. All enrolled patients will be treated with Fostamatinib Disodium until disease progression. Efficacy will be assessed by tumor measurements using CT and PET (when indicated) scans and physical exam at baseline, and scans and physical exam of all disease-involved areas every 8 weeks until progression. Safety will be assessed by periodic physical exams, clinical laboratory studies, and adverse events. All patients will have a follow-up visit 30 days following last study drug treatment. Blood samples for PK assessment will be obtained from all patients enrolled in Stage 1 at protocol defined intervals.


Description:

Up to 61 patients (male and female) meeting the inclusion and exclusion criteria will be enrolled into this trial in two stages. All enrolled patients will be treated with R788 at 200 mg PO bid until disease progression. In the initial stage of the study, a total of 19 patients will be enrolled and treated with Fostamatinib Disodium. Should at least 4 patients exhibit a response at Week 8 or later of the study, the second stage of 36 patients will open to enrollment. Efficacy will be assessed by CT and PET scans (when indicated) and physical exam at baseline, and CT scans and physical exam of all disease-involved areas every 8 weeks until progression. Safety will be assessed by periodic physical exams, clinical laboratory studies, and adverse events. All patients will have a follow-up visit 30 days following last study drug treatment. Blood samples for PK assessment will be obtained from all patients enrolled in Stage 1 at protocol-defined intervals. Patients with accessible tumor tissue will be asked to undergo a biopsy for a fresh tissue sample for assessment of Syk activity in tumor tissue. Archived tissue samples from the initial diagnostic biopsy and the most recent biopsy for lymphoma will be obtained in the event a fresh tumor biopsy cannot be obtained. Patients who have accessible tumor tissue will be asked to consent to a second tumor biopsy at Week 8, to assess the impact of Fostamatinib Disodium treatment on the activity of Syk and its downstream markers. All baseline fresh or archived tumor tissue samples will undergo central pathology review to confirm the diagnosis of TCL.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date April 2010
Est. primary completion date April 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients must give written informed consent to participate in this study by signing an IRB/EC-approved Informed Consent Form (ICF) prior to admission to this study.

- Males and females, 18 years of age or older.

- Patients must have histologically proven T-cell lymphoma (TCL).

- Patients must have documented disease progression after receiving at least one prior therapeutic regimen and must be patients for whom no known curative therapy exists.

Exclusion Criteria:

- Patient has a history of, or a concurrent, clinically significant illness, medical condition or laboratory abnormality that, in the investigator's opinion, could affect the conduct of the study.

- Has a B-cell lymphoma, primary CNS lymphoma, or known lymphomatous involvement of the CNS, or any other NK/T-cell leukemia/lymphoma.

- Has uncontrolled or poorly controlled hypertension.

- Has had recent (within 1 month prior to Day 1) serious surgery or uncontrolled infectious disease.

- Has any concurrent malignancy requiring treatment.

- Has a known positive test for Hepatitis B surface Ag, Hepatitis C, or HIV.

- Has laboratory abnormalities.

- Has difficulty swallowing or malabsorption.

- Has an ECOG performance status > 2.

- Has not recovered from adverse effects related to last prior therapy for lymphoma.

- Has had an allotransplantation within 90 days prior to Day 1 of treatment.

- Has been treated with a CYP3A4 inducer/inhibitor within 3 days prior to Day 1 of treatment or is expected to require treatment with CYP3A4 inducer/inhibitor during the course of the study.

- Has received systemic steroids at a dose greater than the equivalent of 10 mg/day of prednisone within 7 days prior to Day 1 of treatment.

- Has received any other investigational therapy within 5 half-lives of the agent or 2 weeks of Day 1 of treatment, whichever is longer.

- Is a female of childbearing potential unless menopausal, surgically sterile, or willing to use an effective method of birth control, (oral contraceptive, mechanical barrier, long-acting hormonal agent), during the study and for 30 days thereafter.

- Is pregnant or lactating.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Fostamatinib Disodium
200 mg PO BID

Locations

Country Name City State
Canada Research Site Toronto Ontario
Canada Research Site Vancouver British Columbia
United States Research Site Atlanta Georgia
United States Research Site Boston Massachusetts
United States Research Site Houston Texas
United States Research Site New York New York
United States Research Site Omaha Nebraska
United States Research Site Rochester Minnesota
United States Research Site San Francisco California
United States Research Site Stanford California

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Primary Efficacy Endpoint for This Study is Overall Regressive Response Rate (ORRR): Proportion of Patients With a Best Response of Complete Response (CR), Partial Response (PR), or Regressive Stable Disease (RSD). Overall regressive response rate (ORRR) is the proportion of patients with a best response of Complete Response (CR), Partial Response (PR) (per Cheson 2007), or Regressive Stable Disease (RSD) defined as regressive disease that does not meet the criteria for partial response. Serial tumor assessments were taken at baseline (within 28 days of the start of treatment), and re-evaluated at Day 57, and every 8weeks therafter or to confirm response . (Maximum duration of treatment 182 days, Maximum duration of follow-up 217 days) No
Secondary Clinical Benefit Rate is the Proportion of Patients With Best Response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD). Clinical benefit rate is the proportion of patients with best response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD). Serial tumor assessments were taken at baseline (within 28 days of the start of treatment), and re-evaluated at Day 57, and every 8weeks therafter or to confirm response . (Maximum duration of treatment 182 days, Maximum duration of follow-up 217 days) No
Secondary Overall Response Rate (ORR) is the Proportion of Patients With a Best Response of Complete Response (CR) or Partial Response (PR). Overall response rate (ORR) is the proportion of patients with a best response of Complete Response (CR) or Partial Response (PR). Serial tumor assessments were taken at baseline (within 28 days of the start of treatment), and re-evaluated at Day 57, and every 8weeks therafter or to confirm response . (Maximum duration of treatment 182 days, Maximum duration of follow-up 217 days) No
Secondary Duration of Overall Response is the Time From First Documentation of Complete or Partial Response, Whichever Occurs Earlier, to Discontinuation of Study Drug. Duration of Overall Response is the time from first documentation of Complete or Partial Response (Cheson 2007), whichever occurs earlier, to discontinuation of study drug. Serial tumor assessments were taken at baseline (within 28 days of the start of treatment), and re-evaluated at Day 57, and every 8weeks therafter or to confirm response . (Maximum duration of treatment 182 days, Maximum duration of follow-up 217 days) No
See also
  Status Clinical Trial Phase
Recruiting NCT04653649 - CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. Phase 1/Phase 2
Not yet recruiting NCT06420076 - Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells Phase 1/Phase 2
Completed NCT01561833 - A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Phase 1
Withdrawn NCT04334174 - Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas Phase 2
Recruiting NCT05367856 - Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma Phase 2
Completed NCT03770000 - Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma Phase 1/Phase 2
Not yet recruiting NCT05996185 - Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma Phase 2
Active, not recruiting NCT01430013 - Trial of Endostar Combined With CHOPT for T Cell Lymphoma Phase 2
Active, not recruiting NCT04502446 - A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) Phase 1
Terminated NCT04973527 - LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor Phase 1
Recruiting NCT05230680 - Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) Phase 1/Phase 2
Recruiting NCT03672084 - Allo-HSCT as First-line Consolidation in High-risk PTCL
Recruiting NCT05852028 - A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma
Enrolling by invitation NCT03628612 - Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified Phase 2
Recruiting NCT00974324 - Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma Phase 2
Completed NCT00877656 - HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma Phase 2/Phase 3
Not yet recruiting NCT05772728 - Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL) N/A
Completed NCT01300026 - AMG 319 Lymphoid Malignancy FIH Phase 1
Terminated NCT00880867 - Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma Phase 1
Recruiting NCT04840875 - Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma Phase 1